Hermetica Superfood Encyclopedia
The Short Answer
Memecylon edule leaf and flower extracts contain ursolic acid, stearic acid, 1,2,3-benzenetriol (pyrogallol), and diverse flavonoids and tannins, with ursolic acid demonstrating topoisomerase II inhibition via molecular docking and dose-dependent antiproliferative cytotoxicity against U-937 and HL-60 cancer cell lines. In vitro antimicrobial assays recorded a minimum inhibitory concentration of 62.5 µg/mL against pathogens including Streptococcus pneumoniae and Salmonella typhimurium, and flower ethyl acetate extracts achieved up to 94.48% antibiofilm inhibition against Pseudomonas aeruginosa.
CategoryHerb
GroupSoutheast Asian
Evidence LevelPreliminary
Primary KeywordMemecylon edule benefits
Memecylon edule — botanical close-up
Health Benefits
**Antidiabetic and Hypoglycaemic Activity**
Ethnomedicinal use across Malaysia and southern India documents hypoglycaemic application; aqueous and ethyl acetate leaf extracts are considered candidate nutraceuticals for blood glucose management, though in vivo and clinical validation remain limited.
**Antiproliferative and Anticancer Potential**
Ursolic acid isolated from ethyl acetate leaf extracts inhibited topoisomerase II via molecular docking and reduced viability of U-937 lymphoma cells to 73.15 ± 2.01% and HL-60 leukemia cells to 69.64 ± 0.68% at 3.13 µmol/mL, indicating dose-dependent cytotoxicity.
**Antimicrobial Action**: Leaf extracts demonstrated MIC of 62
5 µg/mL and MBC of 1 mg/mL against S. pneumoniae and Salmonella typhimurium (inhibition zone 25 mm), attributed to stearic acid and phenolic compounds disrupting microbial membrane integrity.
**Antibiofilm Activity**: Flower ethyl acetate extracts achieved up to 94
48% inhibition of biofilm formation against P. aeruginosa and 37.40% against E. coli by suppressing microbial cell adhesion, suggesting therapeutic potential against drug-resistant biofilm-associated infections.
**Antioxidant Activity**
Phenolic constituents including 1,2,3-benzenetriol (pyrogallol), epigallocatechin gallate, and myricetin confer free radical scavenging capacity; aqueous extracts have been characterized as candidate nutraceutical antioxidants in preliminary phytochemical assessments.
**Anti-inflammatory and Hepatoprotective Properties**
Traditional ethnomedicinal use in India attributes anti-inflammatory, spasmolytic, and hepatoprotective effects to the plant; triterpenoids including ursolic acid are consistent with known anti-inflammatory mechanisms such as NF-κB pathway modulation, though direct experimental confirmation in M. edule is lacking.
**Larvicidal and Antiviral Applications**
Ethnobotanical records document larvicidal and antiviral uses; these activities are attributed to the cumulative effect of tannins, saponins, and triterpenoid fractions, with no quantified in vitro or in vivo data currently published.
Origin & History
Natural habitat
Memecylon edule Roxb. is a tropical shrub or small tree native to South and Southeast Asia, distributed across India (notably the Shervarayan and Kolli Hills of Tamil Nadu), Sri Lanka, Malaysia, and parts of the Indo-Malayan archipelago. It thrives in humid tropical forests, rocky hillsides, and coastal scrublands at low to moderate elevations, typically in well-drained lateritic or sandy soils under partial shade. The plant is not commercially cultivated at scale; aerial parts including leaves and flowers are primarily wildcrafted by indigenous communities for traditional medicinal use.
“Memecylon edule has a documented history of use in the traditional medicine systems of southern India, particularly among tribal communities of the Shervarayan Hills and Kolli Hills of Tamil Nadu, where it is employed for conditions including leucorrhoea (anti-leucorrhoeic use), spasms, fever, and inflammatory disorders. In Malaysian ethnomedicine, the plant is associated with the treatment of diabetes, aligning with its pharmacologically plausible hypoglycaemic activity and justifying its categorization as a Southeast Asian antidiabetic herb. Preparations traditionally involve the collection of fresh aerial parts—leaves and flowers—followed by aqueous decoction or maceration, with some communities using bark preparations for dermatological conditions. The plant's role in green nanotechnology has also emerged recently, with leaf extracts employed as reducing agents in the biosynthesis of nanoparticles, representing a contemporary extension of its phytochemical utility beyond classical ethnomedicine.”Traditional Medicine
Scientific Research
The available body of evidence for Memecylon edule consists exclusively of in vitro laboratory studies and molecular docking computational analyses; no randomized controlled trials, animal pharmacology studies, or human clinical investigations have been published as of the current literature review. Phytochemical characterization via GC-MS of ethyl acetate leaf extracts identified stearic acid at 20.19% and 1,2,3-benzenetriol at 11.30% peak area, while ursolic acid was isolated and confirmed structurally from the same fraction with antiproliferative assays conducted on two leukemia/lymphoma cell lines (U-937 and HL-60) at a single concentration point of 3.13 µmol/mL. Antimicrobial and antibiofilm studies employed standard disk diffusion and MIC/MBC broth microdilution methods against a limited panel of bacterial strains, yielding reproducible but non-clinically validated results. The overall evidence base is preclinical and exploratory, and the transition from in vitro bioactivity data to demonstrated in vivo or clinical efficacy has not been made for any indication.
Preparation & Dosage
Traditional preparation
**Ethyl Acetate Leaf Extract (Research Grade)**
Used at 62.5 µg/mL for antimicrobial testing and 3.13 µmol/mL ursolic acid equivalent for antiproliferative assays; no human-equivalent dose established.
**Aqueous Leaf Infusion (Traditional)**
Prepared by decocting fresh or dried leaves in water; used in Indian folk medicine for hypoglycaemic and anti-inflammatory purposes without standardized dose or concentration data.
**Flower Ethyl Acetate Extract (Research Grade)**
Evaluated for antibiofilm activity at unspecified concentrations yielding 94.48% P. aeruginosa biofilm inhibition; not formulated for human use.
**Ursolic Acid Isolate**
Extracted via activity-guided fractionation of ethyl acetate leaf extract; tested in vitro at 3.13 µmol/mL; no commercial supplement standardization for M. edule-sourced ursolic acid exists.
**No Standardized Commercial Form**
Capsule, tablet, tincture, or standardized extract formulations have not been developed or approved; all dosage information is experimental and not applicable to human supplementation.
Nutritional Profile
Memecylon edule leaves and flowers contain a diverse array of secondary metabolites rather than notable primary nutritional macronutrients; no food-use proximate composition data (protein, carbohydrate, fat content) are available. Identified phytochemicals by GC-MS in ethyl acetate leaf extracts include stearic acid (a C18 saturated fatty acid, 20.19% peak area), tetracosanoic acid trimethylsilyl ester (lignoceric acid derivative, 8.39%), and 1,2,3-benzenetriol/pyrogallol (11.30%), alongside 2,2-dimethylglutaric acid (8.39%) and 4-vinylphenol (1.73%). Polyphenolic constituents include epigallocatechin gallate (EGCG), myricetin, and other flavonoids; triterpenoids including ursolic acid; tannins; saponins; carotenoids; glucose; and amino acids have been qualitatively identified. Bioavailability of these compounds from crude plant preparations is unknown, as no pharmacokinetic studies specific to M. edule extracts have been conducted.
How It Works
Mechanism of Action
Ursolic acid (3β-hydroxyurs-12-en-28-oic acid), a pentacyclic triterpenoid isolated from ethyl acetate leaf fractions, inhibits DNA topoisomerase II as demonstrated by molecular docking studies, thereby impairing DNA replication and inducing apoptosis in cancer cell lines such as U-937 and HL-60. Stearic acid and phenolic compounds including 1,2,3-benzenetriol (pyrogallol) disrupt bacterial cell membrane lipid bilayers, compromising membrane integrity and leading to cytoplasmic leakage, which accounts for the observed antimicrobial activity at MIC 62.5 µg/mL. Flavonoids such as epigallocatechin gallate and myricetin scavenge reactive oxygen species through hydrogen atom transfer and single-electron transfer mechanisms, contributing to the antioxidant profile, while tannins inhibit bacterial cell adhesion to surfaces, explaining the robust antibiofilm activity in flower extracts. The hypoglycaemic effects reported ethnopharmacologically likely involve inhibition of α-glucosidase or enhancement of insulin sensitivity consistent with the activity of ursolic acid and flavonoids seen in related species, but specific receptor-level or enzyme-level data for M. edule itself have not been published.
Clinical Evidence
No human clinical trials investigating Memecylon edule or its isolated constituents for any health outcome have been conducted or reported in the peer-reviewed literature. The most advanced experimental data derive from in vitro antiproliferative studies showing 73.15 ± 2.01% cell viability reduction in U-937 cells and 69.64 ± 0.68% in HL-60 cells at a fixed concentration of 3.13 µmol/mL ursolic acid, representing dose-response characterization without IC50 determination or in vivo confirmation. Antimicrobial outcomes such as MIC of 62.5 µg/mL and antibiofilm inhibition up to 94.48% are from microplate and agar-based in vitro assays and cannot be extrapolated to clinical dosing without pharmacokinetic data. Confidence in clinical applicability remains very low; M. edule should be regarded as a candidate plant for further preclinical and eventual clinical investigation rather than an evidence-based therapeutic agent.
Safety & Interactions
No formal safety studies, toxicological assessments, or adverse event reports for Memecylon edule or its isolated constituents have been published; the safety profile is therefore entirely uncharacterized in human subjects. In vitro studies at concentrations of 62.5 µg/mL to 3.13 µmol/mL did not report cytotoxicity to normal cell lines, but the absence of cytotoxicity data in non-cancerous primary cells and the complete lack of in vivo toxicological data preclude any safety conclusions. No drug interactions have been documented; however, theoretical interactions with antidiabetic medications (additive hypoglycaemic risk), anticoagulants (given tannin and fatty acid content), and cytotoxic chemotherapy agents (ursolic acid's topoisomerase II activity) cannot be excluded. Use during pregnancy or lactation is not recommended given the absence of safety data; individuals with known plant allergies within the Melastomataceae family should exercise caution.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Memecylon edule Roxb.ironwood treedelek air (Malay)kariungil (Tamil)Memecylon tinctorium
Frequently Asked Questions
What is Memecylon edule used for in traditional medicine?
In traditional medicine across southern India and Malaysia, Memecylon edule is used primarily for its hypoglycaemic (antidiabetic), anti-inflammatory, anti-leucorrhoeic, and spasmolytic properties, with additional applications in treating fever, hepatic conditions, and microbial infections. Tribal communities in the Shervarayan and Kolli Hills of Tamil Nadu prepare aqueous decoctions of the leaves and bark, while Malaysian ethnomedicine employs the plant specifically for diabetes management. These uses are supported by preliminary in vitro pharmacological data but lack clinical trial validation.
What bioactive compounds are found in Memecylon edule?
GC-MS analysis of ethyl acetate leaf extracts identifies stearic acid (20.19% peak area), 1,2,3-benzenetriol or pyrogallol (11.30%), tetracosanoic acid derivative (8.39%), and 2,2-dimethylglutaric acid (8.39%) as major constituents, alongside phenolics such as 4-vinylphenol and epigallocatechin gallate. The triterpenoid ursolic acid (3β-hydroxyurs-12-en-28-oic acid) has been isolated from the ethyl acetate leaf fraction and is considered a primary bioactive compound. Flower extracts additionally contain triterpenes, tannins, flavonoids including myricetin, saponins, carotenoids, and amino acids.
Does Memecylon edule have anticancer properties?
In vitro studies demonstrate that ursolic acid isolated from M. edule ethyl acetate leaf extracts inhibits topoisomerase II as shown by molecular docking, and reduces cell viability of U-937 lymphoma cells to 73.15 ± 2.01% and HL-60 leukemia cells to 69.64 ± 0.68% at a concentration of 3.13 µmol/mL. These results indicate dose-dependent cytotoxic potential against hematological cancer cell lines; however, no animal studies or human clinical trials have been conducted, and the current evidence does not support any clinical anticancer claims for M. edule.
Is Memecylon edule safe to consume as a supplement?
No formal toxicological studies, adverse event reports, or human safety data exist for Memecylon edule; its safety profile is entirely uncharacterized. While in vitro studies at tested concentrations did not report overt cytotoxicity to experimental cell systems, the absence of in vivo toxicology, pharmacokinetic data, and clinical trials means no safe human dose can be defined. Use during pregnancy or lactation is not advisable, and potential interactions with antidiabetic drugs or anticoagulants cannot be ruled out.
How effective is Memecylon edule against bacterial infections?
Ethyl acetate leaf extracts of M. edule demonstrated a minimum inhibitory concentration (MIC) of 62.5 µg/mL and a minimum bactericidal concentration (MBC) of 1 mg/mL against pathogens including Streptococcus pneumoniae and Salmonella typhimurium, with inhibition zones of 25 mm in disk diffusion assays. Flower extracts achieved up to 94.48% antibiofilm inhibition against Pseudomonas aeruginosa and 37.40% against Escherichia coli by suppressing cell adhesion. These are in vitro results only; clinical translation requires pharmacokinetic studies and human trials that have not yet been conducted.
What is the current level of clinical evidence for Memecylon edule's blood sugar management effects?
While traditional medicine systems in Malaysia and southern India have documented hypoglycaemic uses of Memecylon edule for centuries, most supporting evidence comes from in vitro and animal studies rather than human clinical trials. Aqueous and ethyl acetate leaf extracts show promise as candidate nutraceuticals for blood glucose management, but robust in vivo validation and clinical studies in human populations remain limited. This gap between traditional use and modern clinical verification means supplement claims should be viewed with appropriate caution until larger-scale human studies are completed.
Who should consider taking Memecylon edule supplements for metabolic health?
Individuals interested in traditional approaches to blood glucose support, particularly those with family histories of metabolic concerns in South Asian or Malaysian populations where this herb has historical use, may be candidates for Memecylon edule supplementation. However, those with existing diabetes, taking blood sugar medications, or pregnant/nursing should consult healthcare providers before use, as clinical safety data in these populations is insufficient. The herb appears most relevant for people seeking complementary support based on ethnomedicinal traditions rather than as a primary therapeutic intervention.
How does Memecylon edule's extract form affect its potential efficacy for blood glucose management?
Research indicates that ethyl acetate leaf extracts and aqueous extracts of Memecylon edule exhibit different bioactive compound profiles and in vitro potencies for hypoglycaemic activity. The ethyl acetate form appears to concentrate certain active compounds like ursolic acid more effectively than water-based extracts, suggesting potential differences in bioavailability and metabolic effects. However, direct comparative studies evaluating which extract form produces superior results in human supplementation are currently absent, making it difficult to definitively recommend one preparation over another.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w memecylon-edule-memecylon-edule-roxb curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
